Literature DB >> 7768786

Factors affecting the intracellular accumulation and activity of azithromycin.

A Pascual1, M C Conejo, I García, E J Perea.   

Abstract

Azithromycin is a new macrolide which accumulates in high concentrations in human phagocytes. The cellular to extracellular ratio (C/E) of azithromycin concentrations (fixed extracellular concentration 1 mg/L) in human polymorphonuclear leucocytes (PMN) were significantly affected by small increases in the environmental temperature (C/E 20.3 +/- 2 and 59.4 +/- 6 at 37 degrees C and 40 degrees C, respectively). PMN-associated azithromycin was not affected by the presence of different concentrations of human serum. The intracellular accumulation of azithromycin decreased slightly (C/E approximately 5) when cells were activated with PMA or opsonized with zymosan. The phagocytosis of opsonized Staphylococcus aureus or Haemophilus influenzae, however, slightly increased the intracellular concentrations of azithromycin. At different extracellular concentrations, azithromycin did not affect the production of hydrogen peroxide and superoxide radicals by PMN. The intracellular survival of H. influenzae in human PMN was abolished in the presence of concentrations higher than 0.125 mg/L of azithromycin. Under the same experimental conditions, however, azithromycin did not show any intracellular activity against S. aureus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7768786     DOI: 10.1093/jac/35.1.85

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  Azithromycin impact on neutrophil oxidative metabolism depends on exposure time.

Authors:  H Levert; B Gressier; I Moutard; C Brunet; T Dine; M Luyckx; M Cazin; J C Cazin
Journal:  Inflammation       Date:  1998-04       Impact factor: 4.092

2.  Mechanisms of the Macrolide-Induced Inhibition of Superoxide Generation by Neutrophils.

Authors:  Kohji Nozoe; Yoshitomi Aida; Takao Fukuda; Terukazu Sanui; Fusanori Nishimura
Journal:  Inflammation       Date:  2016-06       Impact factor: 4.092

3.  Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance.

Authors:  N I Girgis; T Butler; R W Frenck; Y Sultan; F M Brown; D Tribble; R Khakhria
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

4.  Plectasin shows intracellular activity against Staphylococcus aureus in human THP-1 monocytes and in a mouse peritonitis model.

Authors:  Karoline Sidelmann Brinch; Anne Sandberg; Pierre Baudoux; Françoise Van Bambeke; Paul M Tulkens; Niels Frimodt-Møller; Niels Høiby; Hans-Henrik Kristensen
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

5.  Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages.

Authors:  Cristina Seral; Françoise Van Bambeke; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

6.  Pharmacokinetics of tulathromycin in healthy and neutropenic mice challenged intranasally with lipopolysaccharide from Escherichia coli.

Authors:  N Villarino; S A Brown; T Martín-Jiménez
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

7.  Open label comparative trial of mono versus dual antibiotic therapy for Typhoid Fever in adults.

Authors:  Niv Zmora; Sudeep Shrestha; Ami Neuberger; Yael Paran; Rajendra Tamrakar; Ashish Shrestha; Surendra K Madhup; T R S Bedi; Rajendra Koju; Eli Schwartz
Journal:  PLoS Negl Trop Dis       Date:  2018-04-23

8.  Azithromycin and cefixime combination versus azithromycin alone for the out-patient treatment of clinically suspected or confirmed uncomplicated typhoid fever in South Asia: a randomised controlled trial protocol.

Authors:  Abhishek Giri; Abhilasha Karkey; Sabina Dongol; Amit Arjyal; Archana Maharjan; Balaji Veeraraghavan; Buddhi Paudyal; Christiane Dolecek; Damodar Gajurel; Dung Nguyen Thi Phuong; Duy Pham Thanh; Farah Qamar; Gagandeep Kang; Ho Van Hien; Jacob John; Katrina Lawson; Marcel Wolbers; Md Shabab Hossain; M Sharifuzzaman; Nantasit Luangasanatip; Nhukesh Maharjan; Piero Olliaro; Priscilla Rupali; Ronas Shakya; Sadia Shakoor; Samita Rijal; Sonia Qureshi; Stephen Baker; Subi Joshi; Tahmeed Ahmed; Thomas Darton; Tran Nguyen Bao; Yoel Lubell; Evelyne Kestelyn; Guy Thwaites; Christopher M Parry; Buddha Basnyat
Journal:  Wellcome Open Res       Date:  2021-11-12

9.  Relative effectiveness of azithromycin in killing intracellular Porphyromonas gingivalis.

Authors:  Pin-Chuang Lai; John D Walters
Journal:  Clin Exp Dent Res       Date:  2016-02-05

10.  The emergence of azithromycin-resistant Salmonella Typhi in Nepal.

Authors:  Pham Thanh Duy; Sabina Dongol; Abhishek Giri; Nguyen Thi Nguyen To; Ho Ngoc Dan Thanh; Nguyen Pham Nhu Quynh; Pham Duc Trung; Guy E Thwaites; Buddha Basnyat; Stephen Baker; Maia A Rabaa; Abhilasha Karkey
Journal:  JAC Antimicrob Resist       Date:  2020-12-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.